中度至重度特应性皮炎-话题@MedSci

#中度至重度特应性皮炎#

8篇内容 | 844人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1515424, encodeId=41e6151542436, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何, objectType=article, longId=733964, objectId=3601e3396485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3601e3396485, replyNumber=0, likeNumber=46, createdTime=2022-07-31, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3601e3396485, moduleTitle=J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3601e3396485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515423, encodeId=0dae151542327, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, objectType=article, longId=299190, objectId=b29229919036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29229919036, replyNumber=0, likeNumber=52, createdTime=2022-02-21, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29229919036, moduleTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29229919036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515422, encodeId=40cf15154229f, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, objectType=article, longId=294727, objectId=65f8294e27ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65f8294e27ca, replyNumber=0, likeNumber=33, createdTime=2022-01-27, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65f8294e27ca, moduleTitle=JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65f8294e27ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515421, encodeId=ee521515421b0, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=34, createdTime=2022-01-01, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515420, encodeId=ad5215154208c, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, objectType=article, longId=215845, objectId=09762158451c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09762158451c, replyNumber=0, likeNumber=46, createdTime=2021-08-18, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09762158451c, moduleTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09762158451c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, objectType=article, longId=197603, objectId=36c019e60339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c019e60339, replyNumber=0, likeNumber=33, createdTime=2020-07-17, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c019e60339, moduleTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c019e60339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515418, encodeId=5560151541808, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=0, createdTime=2020-02-03, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515417, encodeId=de3d151541e05, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, objectTitle=礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab, objectType=article, longId=186390, objectId=85b418639058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b418639058, replyNumber=0, likeNumber=33, createdTime=2020-01-18, rootId=0, userName=ms6980045490879608, userId=6ad510789639, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b418639058, moduleTitle=礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b418639058)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

中度至重度特应性皮炎

2020-05-29

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

J Am Acad Dermatol：阿布昔替尼可有效治疗中度至重度特应性皮炎，无论之前患者对度匹鲁单抗的反应如何

2022-07-31

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎

2022-02-21

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

JACIP:Dupilumab治疗减少成人中度至重度特应性皮炎的住院治疗

2022-01-27

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-01-01

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎

2021-08-18

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎

2020-07-17

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-02-03

ms6980045490879608 (审核中...)

前往app查看评论内容

#中度至重度特应性皮炎#

礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab

2020-01-18

科室
- - 订阅+
  - 更多科室
工具
服务